HUTCHMED Advances HMPL-760 into Phase III Trial for Relapsed/Refractory DLBCL
Event summary
- HUTCHMED initiated a Phase III trial of HMPL-760 in combination with R-GemOx for relapsed/refractory DLBCL in China on March 20, 2026.
- The trial aims to enroll 240 patients and is led by Professor Weili Zhao, Vice President of Ruijin Hospital.
- HMPL-760 is a third-generation BTK inhibitor designed to target both wild-type and C481S-mutated BTK.
- Primary outcome measures include progression-free survival (PFS) and overall survival (OS).
- The trial follows encouraging Phase II results showing improved ORR, CRR, PFS, and OS with a manageable safety profile.
The big picture
HUTCHMED's advancement of HMPL-760 into Phase III trials underscores the growing focus on targeted therapies for relapsed/refractory DLBCL, a prevalent and aggressive form of non-Hodgkin lymphoma. The trial's success could position HMPL-760 as a key player in the BTK inhibitor market, particularly given its ability to target both wild-type and mutated BTK. The biopharmaceutical sector continues to prioritize innovative treatments for hematological cancers, driven by the need for more effective and durable responses in relapsed/refractory patients.
What we're watching
- Clinical Trial Progress
- The pace at which HUTCHMED can enroll patients and generate data from this Phase III trial will determine the timeline for potential regulatory approval.
- Regulatory Pathway
- Whether HMPL-760 can secure expedited approval in China and other jurisdictions based on the Phase III results.
- Commercial Strategy
- How HUTCHMED plans to position HMPL-760 in the competitive landscape of BTK inhibitors for DLBCL.
Related topics